180 Life Sciences Corp. to Ring Nasdaq Opening Bell on November 27, 2020

Written by Customer Service on . Posted in Public Companies.

MENLO PARK, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) — 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the “Company”), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will ring the Nasdaq Stock Exchange opening bell on November 27, 2020, in celebration of its recently completed initial public offering.Dr. James Woody, CEO of 180 Life Sciences, will be joined by members of the 180 Life Sciences team for the virtual ceremony, which will begin at approximately 9:20 am Eastern Time, and can be viewed live at https://livestream.com/nasdaq/live and on the Nasdaq MarketSite Tower in Times Square, at 43rd Street and Broadway, New York, NY. The bell ringing will take place at 9:30am Eastern Time, signifying the start of the day’s trading session. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis and inflammation using anti-TNF, with its lead program in phase 2b/3 clinical trial.About 180 Life Sciences Corp.180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The Company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials.Forward-Looking StatementsInvestors:Jason Assad
Director of IR
180 Life Sciences Corp
678-570-6791
Jason@180lifesciences.comMedia Relations:David Schull
David.Schull@russopartnersllc.com
(212) 845-4271Eric Ando
Eric.Ando@russopartnersllc.com  
(646) 218-4604

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.